Bank of New York Mellon Corp Sells 53,175 Shares of Conatus Pharmaceuticals Inc (CNAT)

Share on StockTwits

Bank of New York Mellon Corp reduced its stake in Conatus Pharmaceuticals Inc (NASDAQ:CNAT) by 24.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 165,834 shares of the biotechnology company’s stock after selling 53,175 shares during the period. Bank of New York Mellon Corp owned approximately 0.55% of Conatus Pharmaceuticals worth $711,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. grew its stake in shares of Conatus Pharmaceuticals by 45.4% in the first quarter. BlackRock Inc. now owns 2,316,808 shares of the biotechnology company’s stock worth $13,601,000 after acquiring an additional 723,413 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Conatus Pharmaceuticals by 1,205.7% in the first quarter. JPMorgan Chase & Co. now owns 74,062 shares of the biotechnology company’s stock worth $435,000 after acquiring an additional 68,390 shares during the last quarter. LMR Partners LLP purchased a new stake in shares of Conatus Pharmaceuticals in the second quarter worth $311,000. Wells Fargo & Company MN grew its stake in shares of Conatus Pharmaceuticals by 63.4% in the first quarter. Wells Fargo & Company MN now owns 55,600 shares of the biotechnology company’s stock worth $326,000 after acquiring an additional 21,564 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Conatus Pharmaceuticals by 253.0% in the first quarter. The Manufacturers Life Insurance Company now owns 22,987 shares of the biotechnology company’s stock worth $135,000 after acquiring an additional 16,476 shares during the last quarter. 33.50% of the stock is currently owned by hedge funds and other institutional investors.

Conatus Pharmaceuticals stock opened at $4.77 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.35 and a current ratio of 2.35. Conatus Pharmaceuticals Inc has a one year low of $3.22 and a one year high of $7.95. The firm has a market cap of $155.55 million, a P/E ratio of -7.87 and a beta of 1.38.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its quarterly earnings data on Friday, August 3rd. The biotechnology company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.05. Conatus Pharmaceuticals had a negative return on equity of 69.68% and a negative net margin of 48.46%. The company had revenue of $8.77 million for the quarter, compared to analysts’ expectations of $9.06 million. As a group, equities analysts anticipate that Conatus Pharmaceuticals Inc will post -0.66 EPS for the current fiscal year.

CNAT has been the topic of a number of recent research reports. Zacks Investment Research raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 4th. Oppenheimer set a $14.00 target price on Conatus Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Finally, ValuEngine raised Conatus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, September 22nd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $11.80.

Conatus Pharmaceuticals Profile

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Featured Article: Do stock splits help investors?

Want to see what other hedge funds are holding CNAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Conatus Pharmaceuticals Inc (NASDAQ:CNAT).

Institutional Ownership by Quarter for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

SANDS CHINA Ltd/ADR  Stock Rating Lowered by Deutsche Bank
SANDS CHINA Ltd/ADR Stock Rating Lowered by Deutsche Bank
Lucia Wealth Services LLC Decreases Position in salesforce.com, inc.
Lucia Wealth Services LLC Decreases Position in salesforce.com, inc.
Altria Group Inc  Shares Bought by Rampart Investment Management Company LLC
Altria Group Inc Shares Bought by Rampart Investment Management Company LLC
Paypal Holdings Inc  Position Decreased by Rampart Investment Management Company LLC
Paypal Holdings Inc Position Decreased by Rampart Investment Management Company LLC
Praxair, Inc.  Stake Increased by MUFG Americas Holdings Corp
Praxair, Inc. Stake Increased by MUFG Americas Holdings Corp
Lucia Wealth Services LLC Boosts Position in Clorox Co
Lucia Wealth Services LLC Boosts Position in Clorox Co


© 2006-2018 Ticker Report